These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27404879)

  • 21. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A lifeline for the biotech sector.
    Kessel M
    Nat Biotechnol; 2009 Feb; 27(2):123-4. PubMed ID: 19204686
    [No Abstract]   [Full Text] [Related]  

  • 23. The Human Genome Project: a public good.
    Hudson K
    Health Matrix Clevel; 2002; 12(2):367-75. PubMed ID: 12430360
    [No Abstract]   [Full Text] [Related]  

  • 24. From the analyst's couch: The outlook for biotech exits.
    Grimaldi A
    Nat Biotechnol; 2014 Mar; 32(3):227-8. PubMed ID: 24727772
    [No Abstract]   [Full Text] [Related]  

  • 25. Public biotechnology 2003-the numbers.
    Lähteenmäki R; Baker M
    Nat Biotechnol; 2004 Jun; 22(6):665-70. PubMed ID: 15175683
    [No Abstract]   [Full Text] [Related]  

  • 26. Human genomes, public and private.
    Nature; 2001 Feb; 409(6822):745. PubMed ID: 11236960
    [No Abstract]   [Full Text] [Related]  

  • 27. Biotech weathers 2Q12 slump.
    Yang W
    Nat Biotechnol; 2012 Aug; 30(8):738. PubMed ID: 22871704
    [No Abstract]   [Full Text] [Related]  

  • 28. Pfizer-Pharmacia merger bodes ill for biotech?
    Fletcher L
    Nat Biotechnol; 2002 Sep; 20(9):857-8. PubMed ID: 12205489
    [No Abstract]   [Full Text] [Related]  

  • 29. By the numbers. Drugs/purchasing.
    Mod Healthc; 2003 Dec; Suppl():22. PubMed ID: 14723068
    [No Abstract]   [Full Text] [Related]  

  • 30. Private biotech 2004--the numbers.
    Hodgson J
    Nat Biotechnol; 2006 Jun; 24(6):635-41. PubMed ID: 16763589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sunbaked biotechnology in Australia.
    Littlejohn T
    Nat Biotechnol; 2002 Sep; 20(9):873-7. PubMed ID: 12205502
    [No Abstract]   [Full Text] [Related]  

  • 32. Investors boost Canadian startups but public sector underperforms.
    Waltz E
    Nat Biotechnol; 2012 Aug; 30(8):737. PubMed ID: 22871703
    [No Abstract]   [Full Text] [Related]  

  • 33. Nanobiotech in big pharma: a business perspective.
    Würmseher M; Firmin L
    Nanomedicine (Lond); 2017 Mar; 12(5):535-543. PubMed ID: 28178881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overcoming further challenges in the pharma/biotech industry: 2007 update.
    Graul AI; Cruces E; Revel L; Serradell N; Rosa E
    Drug News Perspect; 2008; 21(1):44-58. PubMed ID: 18301809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Public biotech 2007--the numbers.
    Lawrence S; Lähteenmäki R
    Nat Biotechnol; 2008 Jul; 26(7):753-62. PubMed ID: 18612294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biotech business Down Under.
    Beckley C
    Nature; 2004 Jun; 429(6991 Suppl):5-9. PubMed ID: 15175704
    [No Abstract]   [Full Text] [Related]  

  • 38. The changing norms of the life sciences.
    Shorett P; Rabinow P; Billings PR
    Nat Biotechnol; 2003 Feb; 21(2):123-5. PubMed ID: 12560827
    [No Abstract]   [Full Text] [Related]  

  • 39. Democracy unleashed--unpacking the tooth fairy in drug industry R&D.
    Ozdemir V; Williams-Jones B
    Nat Biotechnol; 2006 Nov; 24(11):1324-6; author reply 1326-7. PubMed ID: 17093467
    [No Abstract]   [Full Text] [Related]  

  • 40. Traditional wheat breeder fights for funding.
    Dalton R
    Nature; 2003 Jun; 423(6942):790. PubMed ID: 12815388
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.